🇺🇸 FDA
Patent

US 10058587

Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

granted A61KA61K31/337A61K31/555

Quick answer

US patent 10058587 (Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity) held by Soricimed Biopharma Inc. expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Soricimed Biopharma Inc.
Grant date
Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/337, A61K31/555, A61K38/00, A61K38/1761